IDiyas

For the Inventor, By the Inventor

Madison, CT, United States of America

Jianliang Shi

USPTO Granted Patents = 17 

 

Average Co-Inventor Count = 7.4

ph-index = 4

Forward Citations = 94(Granted Patents)


Location History:

  • Hamden, CT (US) (2008 - 2010)
  • Hamdem, CT (US) (2011)
  • Madison, CT (US) (2011 - 2015)
  • Furlong, PA (US) (2021 - 2023)

Company Filing History:

goldMedal17 out of 3,681 
 
Bristol-myers Squibb Compnay
 patents

Years Active: 2008-2024

Loading Chart...
Loading Chart...
17 patents (USPTO):
1. 12157733 - Aminotriazolopyridines as kinase inhibitors (2024-12-03),
2. 12110290 - Triazolopyridinyl compounds as kinase inhibitors (2024-10-08),
3. 11767322 - Triazolopyridinyl compounds as kinase inhibitors (2023-09-26),
4. 11618753 - Aminopyrrolotriazines as kinase inhibitors (2023-04-04),
5. 11440913 - Aminoimidazopyridazines as kinase inhibitors (2022-09-13),
6. 10913738 - Aminotriazolopyridines as kinase inhibitors (2021-02-09),
7. 9221796 - Selective NR2B antagonists (2015-12-29),
8. 8710061 - Compounds for the reduction of β-amyloid production (2014-04-29),
9. 8637525 - Compounds for the reduction of beta-amyloid production (2014-01-28),
10. 8604024 - Compounds for the reduction of beta-amyloid production (2013-12-10),
11. 8486952 - Compounds for the reduction of β-amyloid production (2013-07-16),
12. 8349880 - Bicyclic compounds for the reduction of beta-amyloid production (2013-01-08),
13. 7981913 - Isophthalates as beta-secretase inhibitors (2011-07-19),
14. 7902218 - Substituted tetrahydroisoquinolines as β-secretase inhibitors (2011-03-08),
15. 7745470 - Isophthalates as beta-secretase inhibitors (2010-06-29),

Title: The Inventive Journey of Jianliang Shi

Introduction: Jianliang Shi, a prolific inventor based in Madison, CT (US), has made significant contributions in the field of kinase modulation. With an impressive portfolio of 15 patents, his innovative work has led to advancements in treatments related to necrosis, inflammation, and other critical indications.

Latest Patents: Among his recent patents, Jianliang Shi has developed Triazolopyridinyl compounds as kinase inhibitors, which have shown promise in RIPK1 modulation. Additionally, his Aminopyrrolotriazines as kinase inhibitors have demonstrated efficacy in kinase modulation, offering potential solutions in various medical conditions.

Career Highlights: Jianliang Shi is a valued member of Bristol-Myers Squibb Company, a renowned pharmaceutical firm. His expertise and dedication have played a pivotal role in the company's research and development efforts, driving innovation in the realm of kinase modulation and drug discovery.

Collaborations: Throughout his career, Jianliang Shi has collaborated closely with esteemed colleagues such as John E Macor and Lorin A Thompson III. Their combined expertise and teamwork have enabled groundbreaking discoveries and advancements in the pharmaceutical industry.

Conclusion: Jianliang Shi's inventive spirit and commitment to scientific excellence have established him as a key figure in the field of kinase modulation. His patents and collaborations reflect a legacy of innovation that continues to shape the landscape of pharmaceutical research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…